Cargando…

Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy

Diabetic retinopathy is the leading cause of blindness in working age adults, and is projected to be a significant future health concern due to the rising incidence of diabetes. The recent advent of anti-vascular endothelial growth factor (VEGF) antibodies has revolutionized the treatment of diabeti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bolinger, Mark T., Antonetti, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037775/ https://www.ncbi.nlm.nih.gov/pubmed/27618014 http://dx.doi.org/10.3390/ijms17091498

Ejemplares similares

Using the Past to Inform the Future: Anti-VEGF Therapy as a Road Map to Develop Novel Therapies for Diabetic Retinopathy
por: Titchenell, Paul M., et al.
Publicado: (2013)

Leukostasis retinopathy treated with Anti-VEGF therapy
por: Shakibai, Nasim, et al.
Publicado: (2020)

Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy
por: Wang, Tianqin, et al.
Publicado: (2021)

Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population
por: Pramanik, Subhasish, et al.
Publicado: (2021)

A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy
por: Raman, Rajiv, et al.
Publicado: (2022)

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy
por: Bahr, Tyler A., et al.
Publicado: (2023)

Diabetic Retinopathy and VEGF
por: Gupta, N, et al.
Publicado: (2013)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
por: Zhao, Yue, et al.
Publicado: (2018)

microRNA Expression Profile in the Vitreous of Proliferative Diabetic Retinopathy Patients and Differences from Patients Treated with Anti-VEGF Therapy
por: Friedrich, Julian, et al.
Publicado: (2020)

TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy
por: Bonfiglio, Vincenza, et al.
Publicado: (2020)

Effects of Novel Anti-VEGF Agents with Intravitreal Conbercept in Diabetic Retinopathy: A Systematic Review and Meta-Analysis
por: Wang, Hui, et al.
Publicado: (2021)

The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment
por: Tremolada, Gemma, et al.
Publicado: (2012)

Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy
por: Wang, Haibo
Publicado: (2016)

The Association of Intravitreal Anti-VEGF Injections With Kidney Function in Diabetic Retinopathy
por: Bunge, Casey C., et al.
Publicado: (2023)

A case of anti-VEGF therapy application in Takayasu arteries with retinopathy
por: Gong, Qiaoyun, et al.
Publicado: (2020)

Novel therapies for diabetic retinopathy
por: Kupis, Magdalena, et al.
Publicado: (2022)

Anti-VEGF in a Marathon Runner's Retinopathy Case
por: Soon, Alexander Kahjun, et al.
Publicado: (2016)

Progress of Imaging in Diabetic Retinopathy—From the Past to the Present
por: Horie, Shintaro, et al.
Publicado: (2022)

Optical coherence tomography angiography in patients with diabetic retinopathy treated with anti-VEGF intravitreal injections: Case report
por: Michalska-Małecka, Katarzyna, et al.
Publicado: (2017)

Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy
por: Parravano, Mariacristina, et al.
Publicado: (2022)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections
por: Levin, Ariana M, et al.
Publicado: (2017)

Simulation of long-term impact of intravitreal anti-VEGF therapy on patients with severe non-proliferative diabetic retinopathy
por: Nguyen, Quan Dong, et al.
Publicado: (2023)

Aqueous concentrations of VEGF and soluble VEGF receptor-1 in diabetic retinopathy patients
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2012)

Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era
por: Hsu, Ya-Jui, et al.
Publicado: (2014)

Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy
por: Takayama, Kei, et al.
Publicado: (2021)

Long Non-Coding RNAs Gene Variants as Molecular Markers for Diabetic Retinopathy Risk and Response to Anti-VEGF Therapy
por: Mohammad, Hala M F, et al.
Publicado: (2021)

Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity
por: Hartnett, M. Elizabeth, et al.
Publicado: (2023)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

A review on the effect of garlic on diabetes, BDNF, and VEGF as a potential treatment for diabetic retinopathy
por: Sanie-Jahromi, Fatemeh, et al.
Publicado: (2023)

ERK5 Contributes to VEGF Alteration in Diabetic Retinopathy
por: Wu, Yuexiu, et al.
Publicado: (2010)

Fisetin Prevents Angiogenesis in Diabetic Retinopathy by Downregulating VEGF
por: Lai, Meihua, et al.
Publicado: (2023)

Tumor refractoriness to anti-VEGF therapy
por: Ribatti, Domenico
Publicado: (2016)

Classification of diabetic retinopathy: Past, present and future
por: Yang, Zhengwei, et al.
Publicado: (2022)

Efficacy of Prophylactic Anti-VEGF in Preventing Radiation Retinopathy: A Systematic Review and Meta-Analysis
por: Victor, Andi Arus, et al.
Publicado: (2023)

Anti-Inflammatory Therapy in Diabetic Retinopathy
por: Zorena, Katarzyna
Publicado: (2014)

The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy
por: Kuiper, Esther J., et al.
Publicado: (2008)

Anti-VEGF Therapy and the Retina: An Update
por: Tah, Vikas, et al.
Publicado: (2015)

One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema
por: Zhou, Qingyun, et al.
Publicado: (2019)

Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy
por: Hakki, Morgan
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5splimr8bkbkq98r0pf0845psj